one8zero8 LLC Invests $1.66 Million in Pfizer Inc. (NYSE:PFE)

one8zero8 LLC purchased a new position in shares of Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 62,407 shares of the biopharmaceutical company’s stock, valued at approximately $1,656,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Swedbank AB boosted its holdings in Pfizer by 0.7% in the third quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock valued at $166,284,000 after acquiring an additional 37,636 shares during the last quarter. United Bank boosted its holdings in Pfizer by 3.7% in the third quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock valued at $1,030,000 after acquiring an additional 1,277 shares during the last quarter. GSA Capital Partners LLP boosted its holdings in Pfizer by 87.6% in the third quarter. GSA Capital Partners LLP now owns 32,786 shares of the biopharmaceutical company’s stock valued at $949,000 after acquiring an additional 15,310 shares during the last quarter. Curi RMB Capital LLC boosted its holdings in Pfizer by 4.7% in the third quarter. Curi RMB Capital LLC now owns 55,770 shares of the biopharmaceutical company’s stock valued at $1,614,000 after acquiring an additional 2,487 shares during the last quarter. Finally, CIBC Asset Management Inc boosted its holdings in Pfizer by 6.2% in the third quarter. CIBC Asset Management Inc now owns 1,065,338 shares of the biopharmaceutical company’s stock valued at $30,831,000 after acquiring an additional 61,988 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Price Performance

Shares of NYSE:PFE opened at $25.74 on Friday. The firm has a market capitalization of $145.85 billion, a price-to-earnings ratio of 18.25, a PEG ratio of 0.64 and a beta of 0.61. The stock’s 50 day moving average is $26.24 and its 200-day moving average is $27.13. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same period last year, the business earned $0.10 EPS. The business’s revenue was up 24.7% on a year-over-year basis. Sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on PFE shares. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Wednesday. StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Citigroup cut their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Finally, Truist Financial cut their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.